Why the study?
Does genotyping provide added benefit to predict ischaemic and bleeding risk in ACS patients undergoing phenotype-guided de-escalation of anti-platelet treatment?
Does genotyping provide added benefit to predict ischaemic and bleeding risk in ACS patients undergoing phenotype-guided de-escalation of anti-platelet treatment?
Genotyping does not appear to offer additional predictive value for ischemic and bleeding risks in ACS patients already managed with a phenotype-guided de-escalation strategy for anti-platelet therapy.
Answers are grounded in this paper and cite their sources.
Genotyping adds no predictive value to phenotype-guided de-escalation in ACS; hypothesis-generating and should not yet change practice.
BACKGROUND: genotypes correlate with on-treatment platelet reactivity (PR) in ACS patients treated with clopidogrel or prasugrel and thus might be useful for guidance of early de-escalation of anti-platelet treatment. METHODS AND CONCLUSION: carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment. Regarding phenotype-guided treatment, we did not observe added benefit of genotyping to predict ischaemic and bleeding risk in patients who underwent a PGDE approach. CLINICAL TRIAL REGISTRATION: URL: https//www.clinicaltrials.gov. Unique Identifier: NCT: 01959451.
No takes yet. Share an insight, caveat, or question.
Groß et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: